 Home > Active Ingredient News > Endocrine System > Microchip Technology: Cioroni is approved for clinical trial in the treatment of relapsed/refractory SCLC

Microchip Technology: Cioroni is approved for clinical trial in the treatment of relapsed/refractory SCLC

 Last Update: 2021-05-02
 Source: Internet
 Author: User

Tags

soap molecule structure

2 naphthol structure

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On April 16, Microchip announced that the company has recently received an approval from the U.

Currently, Xiao Luo Nigeria will be carried out in addition to the treatment of relapsed / refractory small cell lung cancer clinical trials 1b / 2 period American experience, but also at the same time being the country to carry out small-cell lung cancer monotherapy and in combination with paclitaxel treatment three ovarian cancer treatment clinical trials, the treatment of liver cancer, breast cancer, lymphoma, other gods of different stages of multiple indications of neuroendocrine tumors.

Nigeria will be carried out in addition to the treatment of relapsed / refractory small cell lung cancer in the United States clinical trials 1b / 2 Qi field inspection, while also being carried out domestic monotherapy and in combination with paclitaxel-small cell lung cancer treatment therapy for ovarian cancer Phase III clinical trials, treatment of liver cancer , breast cancer, lymphoma, other gods of different stages of neuroendocrine tumors and other indications.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.